Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Mumbai-based Nicholas Piramal India Ltd. and Eli Lilly & Co. have reached a second drug discovery agreement. NPIL and Lilly will separately conduct early clinical development on different drug candidates directed at the same biological target. NPIL stands to gain as much as $110 million in milestones and royalties if the program is successful. Last year, NPIL licensed a Lilly compound in order to conduct preclinical and clinical studies.
This article has been sent to the following recipient: